Can-Fite Initiates Phase 3 Study of Oral Piclidenoson in PsO With FDA, EMA
Can-Fite BioPharma Ltd. has started a Phase 3 psoriasis study of its oral drug Piclidenoson with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).